


Next-generation HIV immunotherapy: TCR technology

Engineered T-cell therapy that targets hidden HIV-infected cells using HLA-E recognition, offering a universal, next-generation immunotherapy with potential for long-term viral control or cure.

Our breakthrough technology harnesses the body's immune power to fight HIV at its source.

Applications: T cell receptor (TCR) therapy, Engineered T cells, HLA-E restricted immunity, HIV-1 treatment



Features	Benefits
Smart HIV Targeting	Our T-cell receptors (TCRs) are designed to recognise hidden HIV fragments presented by a unique immune molecule (HLA-E). This helps overcome HIV's ability to hide and mutate, offering broader protection across patients
Precision-Engineered Receptors	Each TCR is built from well-defined genetic sequences, ensuring consistent quality, predictable performance, and easier regulatory approval

Features	Benefits
Gene-Based Delivery	We use advanced DNA or RNA vectors to insert these TCRs into immune cells. This allows efficient, scalable manufacturing of patient-ready cell therapies
Engineered Immune Cells	T cells equipped with our TCRs can seek out and destroy HIV-infected cells—potentially leading to long-term viral control or even functional cure
Transformative HIV Treatment Potential	Designed to work alongside or beyond antiretroviral therapy (ART), this approach could redefine how HIV is managed and move us closer to ending the epidemic

Awaiting patent and Available for

- Co-development
- Consulting
- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.